The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its revenues from cardio-metabolic therapeutic segment, and has adopted a “Full Service” approach to diabetes management with a comprehensive range of oral anti-diabetics, insulins, and glucose testing devices.
